Search alternatives:
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
-
21
-
22
-
23
NatB inactivation decreased the level of MAPK and proposed model of EGFR/MAPK signaling regulation by NatB and the N-end rule pathways.
Published 2020“…<p>(A-B) <i>psid-D1</i> (A) or <i>psid-D4</i> (B) clones in 3rd instar fat body, which were marked by GFP expression (pointed by arrowheads), showed decreased MAPK levels (anti-MAPK staining, red). …”
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
-
36
-
37
-
38
-
39
-
40
GSK343 decreased tumor stemness.
Published 2021“…Treatment with GSK343 significantly decreased tumorsphere formation by both the COA3 (A) and COA6 (B) cells, representing a decrease in stem cell-like phenotype. …”